Which class of drugs does neratinib/neratinib (He Li'an) belong to?

Neratinib/Neratinib (Neratinib) is a targeted therapy drug mainly used to treat HER2-positive breast cancer. Specifically, neratinib belongs to the tyrosine kinase inhibitor (TKI) class of drugs. As a targeted therapy drug, neratinib blocks the proliferation signals of cancer cells by inhibiting the HER2 receptor and its related tyrosine kinase activity, thereby reducing the growth and spread of cancer cells.

In the treatment of breast cancer, HER2 receptor is an important oncogenic factor. HER2-positive breast cancer patients usually have overexpressed HER2 receptors on the surface of tumor cells, leading to rapid proliferation and spread of cancer cells. As a second-generation tyrosine kinase inhibitor, neratinib provides a further treatment option based on the existing trastuzumab (Herceptin) treatment. Especially in the extended adjuvant treatment of early-stage breast cancer, neratinib is used to prevent disease recurrence. Neratinib may also be used in combination with capecitabine for the treatment of patients with advanced or metastatic HER2-positive breast cancer, particularly those who have received two or more anti-HER2 therapies in the metastatic setting.

In the treatment of early breast cancer, neratinib works by inhibiting the excessive activation of theHER2 signaling pathway, reducing the proliferation ability of tumor cells, thereby reducing the spread of cancer cells, especially after trastuzumab treatment, helping to prevent cancer recurrence. Unlike traditional chemotherapy drugs, neratinib has higher specificity and lower systemic toxicity by precisely targeting the HER2 receptor, which gives it significant advantages in the treatment of HER2-positive breast cancer.

As a tyrosine kinase inhibitor, neratinib has shown significant efficacy in clinical treatment for HER2-positive breast cancer patients, and its side effects are relatively controllable. Especially in patients with advanced breast cancer, the effect of neratinib in combination with other drugs has been well clinically verified.

Reference materials:https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf